[Homocysteine as a coronary risk factor].
In the results numerouses clinical and epidemiological trials have shown that high level of blood homocysteine is a marker of increased risk of coronary, cerebral and peripheral atherosclerosis. Close relation between high level of homocysteine and enhanced platelet aggregation, its prooxidant action, ability to inhibit growth of endothelial cells constituted basis for proposal of homocysteine theory of atherosclerosis. In this review use soy, products its processing, folate and vitamins B6 and B12 as homocysteine reducing therapy has been also suggested in the treatment of the patients with cardiovascular diseases.
Derbeneva
S A
SA
Pogozheva
A V
AV
D000434:Alcoholic Beverages; D001161:Arteriosclerosis / Q000097:blood / Q000175:diagnosis / Q000178:diet therapy; D002318:Cardiovascular Diseases / Q000178:diet therapy; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000175:diagnosis / Q000209:etiology*; D004032:Diet; D005260:Female; D005492:Folic Acid / Q000627:therapeutic use; D006710:Homocysteine / Q000097:blood* / Q000502:physiology*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000209:etiology / Q000378:metabolism; D008297:Male; D010974:Platelet Aggregation; D012307:Risk Factors; D013025:Glycine max; D014805:Vitamin B 12 / Q000627:therapeutic use; D025101:Vitamin B 6 / Q000627:therapeutic use
D006710:Homocysteine; D025101:Vitamin B 6; D005492:Folic Acid; D014805:Vitamin B 12